Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2015

01-02-2015 | Translational Research and Biomarkers

Decreased Expression of FOXJ1 is a Potential Prognostic Predictor for Progression and Poor Survival of Gastric Cancer

Authors: Jing Wang, MD, Xiqiang Cai, MD, Limin Xia, MD, Jinfeng Zhou, MD, Jing Xin, PhD, Muhan Liu, PhD, Xin Shang, MD, Jian Liu, MD, Xiaowei Li, MD, Zhangqian Chen, MD, Yongzhan Nie, MD, PhD, Daiming Fan, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2015

Login to get access

Abstract

Background

FOXJ1 is a member of the forkhead transcription factor family, which has been mostly studied for its role in the development of ciliated epithelium and immunology. However, the role of FOXJ1 in tumorigenesis remains largely unknown or even conflicting. We thus investigated FOXJ1 expression in gastric cancer and analyzed its correlations with tumor progression and prognosis.

Methods

The expression of FOXJ1 was detected by immunohistochemistry in 105 gastric cancer samples and adjacent noncancerous tissues. Staining evaluation was conducted to assess clinicopathological parameters and the survival rate. In addition, the relation between FOXJ1 and metastasis was investigated in another 40 pairs of primary lesions and corresponding lymph node metastases. Furthermore, cell proliferation, migration, and invasion were confirmed in vitro.

Results

Decreased FOXJ1 expression was significantly correlated with clinic stage, lymph node metastasis, and distant metastasis, and lower FOXJ1 expression independently predicted shorter survival time in gastric carcinoma. Moreover, the positive incidence of FOXJ1 decreased significantly in metastatic lymph nodes compared with that in the primary lesions. Consistently, FOXJ1 overexpression significantly weakened cell proliferation, motility, migration, and invasion, while FOXJ1 knockdown induced the opposite effects.

Conclusions

Decreased expression of FOXJ1 is an independent prognostic predictor for gastric cancer and is critical to disease progression. FOXJ1 may be an attractive therapeutic target for the treatment of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
3.
Shah MA, Ajani JA. Gastric cancer: an enigmatic and heterogeneous disease. JAMA. 2010;303:1753–4.PubMedCrossRef
4.
5.
Ilson DH. Angiogenesis in gastric cancer: hitting the target? Lancet. 2014;383(9911):4–6.
6.
Nishida T. Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet. 2012;379(9813):291–2.PubMedCrossRef
7.
Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.PubMedCrossRef
8.
Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4:889–99.PubMedCrossRef
9.
Zhang H, Meng F, Liu G, et al. Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011;71:1292–301.PubMedCentralPubMedCrossRef
10.
Kim IM, Ackerson T, Ramakrishna S, et al. The forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006;66:2153–61.PubMedCrossRef
11.
Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57:610–24.PubMedCrossRef
12.
Xia L, Huang W, Tian D, et al. FoxQ1 promotes hepatocellular carcinoma metastasis by trans-activating ZEB2 and VersicanV1 expression. Hepatology. 2014;59:958–73.PubMedCrossRef
13.
Zhu JL, Song YX, Wang ZN, et al. The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology. 2013;62:1038–48.PubMedCrossRef
14.
Feng Y, Wang L, Zeng J, et al. FoxM1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res. 2013;11:834–44.PubMedCrossRef
15.
Okada K, Fujiwara Y, Takahashi T, et al. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol. 2013;20:1035–43.PubMedCrossRef
16.
Liang SH, Yan XZ, Wang BL, et al. Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer. Tumour Biol. 2013;34:2605–9.PubMedCrossRef
17.
Li Q, Zhang N, Jia Z, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69:3501–9.PubMedCentralPubMedCrossRef
18.
Cheng AS, Li MS, Kang W, et al. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology. 2013;144:122–133.e9.PubMedCrossRef
19.
Yamamura Y, Lee WL, Inoue K, et al. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem. 2006;281:5267–76.PubMedCrossRef
20.
Clevidence DE, Overdier DG, Tao W, et al. Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. Proc Natl Acad Sci USA. 1993;90:3948–52.PubMedCentralPubMedCrossRef
21.
Cruz C, Ribes V, Kutejova E, et al. Foxj1 regulates floor plate cilia architecture and modifies the response of cells to sonic hedgehog signalling. Development. 2010;137:4271–82.PubMedCentralPubMedCrossRef
22.
Stubbs JL, Vladar EK, Axelrod JD, Kintner C. Multicilin promotes centriole assembly and ciliogenesis during multiciliate cell differentiation. Nat Cell Biol. 2012;14:140–7.PubMedCentralPubMedCrossRef
23.
Lin L, Brody SL, Peng SL. Restraint of B cell activation by Foxj1-mediated antagonism of NF-kappa B and IL-6. J Immunol. 2005;175:951–8.PubMedCrossRef
24.
Lin L, Spoor MS, Gerth AJ, et al. Modulation of Th1 activation and inflammation by the NF-kappaB repressor Foxj1. Science. 2004;303(5660):1017–20.PubMedCrossRef
25.
26.
Siu MK, Wong ES, Kong DS, et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 2013;32:3500–9.PubMedCrossRef
27.
Chen HW, Huang XD, Li HC, et al. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients’ prognosis and tumor cell proliferation. Mol Carcinog. 2013;52:647–59.PubMedCrossRef
28.
Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237–41.PubMed
29.
30.
Bai F, Guo X, Yang L, et al. Establishment and characterization of a high metastatic potential in the peritoneum for human gastric cancer by orthotopic tumor cell implantation. Dig Dis Sci. 2007;52:1571–8.PubMedCrossRef
31.
Zhao X, Dou W, He L, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32:1363–72.PubMedCrossRef
32.
Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.PubMedCrossRef
33.
Xia L, Huang W, Tian D, et al. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:600–12.PubMedCrossRef
Metadata
Title
Decreased Expression of FOXJ1 is a Potential Prognostic Predictor for Progression and Poor Survival of Gastric Cancer
Authors
Jing Wang, MD
Xiqiang Cai, MD
Limin Xia, MD
Jinfeng Zhou, MD
Jing Xin, PhD
Muhan Liu, PhD
Xin Shang, MD
Jian Liu, MD
Xiaowei Li, MD
Zhangqian Chen, MD
Yongzhan Nie, MD, PhD
Daiming Fan, MD, PhD
Publication date
01-02-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3742-2

Other articles of this Issue 2/2015

Annals of Surgical Oncology 2/2015 Go to the issue

Thoracic Oncology

Risk Factors for Weight Loss Among Patients Surviving 5 Years After Esophageal Cancer Surgery

Bone and Soft Tissue Sarcomas

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

Colorectal Cancer

Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial

Breast Oncology

Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction After Contralateral Prophylactic Mastectomy

Colorectal Cancer

Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome

Pancreatic Tumors

Preoperative FDG-PET Predicts Early Recurrence and a Poor Prognosis After Resection of Pancreatic Adenocarcinoma